NEW YORK (GenomeWeb News) – Genzyme Genetics has sublicensed rights for diagnostic testing of epidermal growth factor receptor mutations in non-small cell lung cancer to Manchester, UK-based DxS, the firms announced today.
 
The license grants DxS worldwide rights, except for North America and Hong Kong, to commercialize diagnostic and research products that detect mutations in the kinase domain of the EGFR gene.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.